BioNTech SE (BNTX) stock
BNTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$83.26−1.60 (-1.89%)
Close on Nov 18, 2026Market cap $20.92BP/E –Yield –
BioNTech gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
For fiscal 2025 it was €2.23B, up 0.8% from the year before. The highest annual figure on record is €16.07B in fiscal 2021.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €2.23B | +0.8% |
| FY2024 | Dec 31, 2024 | €2.21B | -31.4% |
| FY2023 | Dec 31, 2023 | €3.22B | -77.5% |
| FY2022 | Dec 31, 2022 | €14.32B | -10.9% |
| FY2021 | Dec 31, 2021 | €16.07B | +3697.9% |
| FY2020 | Dec 31, 2020 | €423.00M | +363.7% |
| FY2019 | Dec 31, 2019 | €91.23M | -19.9% |
| FY2018 | Dec 31, 2018 | €113.89M | +117.8% |
| FY2017 | Dec 31, 2017 | €52.28M | – |
See a number that looks wrong?